Dec 2, 2021
Bob Connelly is the CEO of Elicio Therapeutics which has figured out how to deliver immunotherapies from vaccines into the lymph nodes where they are activated to defeat cancer and infectious diseases.
Bob says, "Our overall mission is to treat many different types of cancers primarily, but even to bring our technology into other areas like infectious diseases by engaging the lymph nodes, which are really the command center for the immune response in our body."
"And to date, they really have not been a part of the cancer immunotherapy revolution that's really started over the last ten years and is very exciting. We're using a technology that initially is focused on KRAS mutation-driven cancers, which comprise 25% of all solid tumors. So we're in a trial right now where we have colorectal cancer patients, we have pancreatic cancer patients, but our lead program can apply in lung cancer, ovarian cancer, bile duct cancer."
"In our bodies, albumin is a very large protein that is constantly circulating throughout the body from lymph node to lymph node. We basically hitchhike on that albumin. We've developed a technology that allows us to hitchhike on that albumin to the lymph nodes, and then hop off into the lymph node, be taken up into the lymph node where all the various aspects of the lymph node can then be brought to bear, to activate the therapeutic, expand it, and send it out on its mission."
@ElicioTX #CancerVaccine #PancreaticCancer #Immunotherapy #lymphnodetargeting #Vaccines #KRASMutation